[ad_1]
Johnson & Johnson became the fourth pharmaceutical group to launch a phase 3 clinical trial of an experimental single-dose coronavirus vaccine in the United States, with 60,000 volunteers on three continents.
RELEVANT ARTICLES
If the results are positive, the company hopes to be able to apply for an urgent license from the US Drug Enforcement Administration (FDA) “in early 2021,” according to a press release issued.
Modern technology company Moderna was the first in the United States to launch a Phase 3 clinical trial in July, which will track the product’s effectiveness on a large scale, in thousands of volunteers. It was followed by the Pfizer Group and its partner BioNTech, then AstraZeneca.
Four experimental vaccines are already in this advanced stage of development
“The fact that four experimental vaccines are already in this advanced stage of development, less than eight months after the virus was identified, is unprecedented,” said Anthony Fauci, director of the US Institute of Infectious Diseases. In a separate press release.
“We may need different types of vaccines to meet global needs,” he said.
Johnson & Johnson, which has committed to distributing the vaccine to the nonprofit company, expects to be able to provide 1 billion doses of the vaccine each year.
[ad_2]
